Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN)

Tipranks - Tipranks - Thu Apr 16, 7:03AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN) with bullish sentiments.

Claim 30% Off TipRanks

Roivant Sciences (ROIV)

In a report released today, Corinne Johnson from Goldman Sachs maintained a Buy rating on Roivant Sciences, with a price target of $41.00. The company’s shares closed last Tuesday at $29.12.

According to TipRanks.com, Johnson is a 4-star analyst with an average return of 8.5% and a 50.0% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Rhythm Pharmaceuticals, and Syndax Pharmaceuticals. ;'>

Currently, the analyst consensus on Roivant Sciences is a Strong Buy with an average price target of $33.89, which is a 16.8% upside from current levels. In a report issued on April 2, TipRanks – PerPlexity also upgraded the stock to Buy with a $31.00 price target.

See the top stocks recommended by analysts >>

Ovid Therapeutics (OVID)

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Ovid Therapeutics, with a price target of $7.00. The company’s shares closed last Tuesday at $2.96, close to its 52-week high of $3.45.

According to TipRanks.com, Chico is a 5-star analyst with an average return of 12.2% and a 51.7% success rate. Chico covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ultragenyx Pharmaceutical, and Apellis Pharmaceuticals. ;'>

Ovid Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.00, a 79.2% upside from current levels. In a report issued on April 8, TipRanks – PerPlexity also upgraded the stock to Buy with a $3.00 price target.

Legend Biotech (LEGN)

Goldman Sachs analyst Ziyi Chen maintained a Buy rating on Legend Biotech yesterday and set a price target of $44.76. The company’s shares closed last Tuesday at $18.69.

According to TipRanks.com, Chen is ranked #5204 out of 12179 analysts.

Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $53.73, implying a 201.0% upside from current levels. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $62.00 price target.

Read More on ROIV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).